Taken together, treatment with the combination of Velcade and ZSTK474 was highly effective against GBM and might have a role in the future therapy for this aggressive disease

Taken together, treatment with the combination of Velcade and ZSTK474 was highly effective against GBM and might have a role in the future therapy for this aggressive disease. == Materials and methods == == Glioma cell lines == Human GBM cell lines U87 and U118 were maintained in Dulbeccos modified Eagles medium (Gibco, BRL) with 10% fetal calf serum (Gemini Bio-Products, Calabasas, CA, USA). novel approach to the treatment of solid tumors (2). Velcade (PS-341/bortezomib) is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome and Carmofur the first proteasome inhibitor evaluated in clinical trials (1,3) and approved by the US Food and Drug Administration (FDA). We previously found that Velcade had profound effects on the growth and apoptosis of GBM cells (4). However, in this study, we found that Velcade simultaneously caused an increase in P-Akt and left RGS5 mTOR signaling active in GBM cells. Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and known as having one of the worst prognoses of all cancers. Successful treatment for GBM is rare. The median survival for patients is 1012 months, despite aggressive surgical approaches, optimized radiation therapy regimens and cytotoxic chemotherapies (5). The PI3K/Akt pathway in GBM cells is highly active, making it an ideal target for cancer therapy (5). Phosphatidylinositol 3-kinases (PI3Ks) are a class of lipid kinases active in signal transduction that generate phosphatidylinostiol-3,4,5-triphosphate (PIP3) by phosphorylating phosphatidylinositol-4,5-bisphosphate (6). They are involved in various cellular processes, including cell proliferation, adhesion, survival and motility, all of which are critical for tumorigenesis (7). Mutation and/or amplification of PI3K genes have been reported in many cancer cells, including glioblastoma (7,8). PI3Ks are activated by receptor tyrosine kinases (RTKs). GBM cells commonly overexpress the oncogene epidermal growth factor receptor (EGFR) and the platelet derived growth factor receptor (PDGFR), both of which are the most common RTKs (9). Downstream of these receptors, the tumor suppressor gene PTEN, is also commonly mutated, further promoting the activation of PI3K/AKT pathway (5). Activation of PI3K pathway members, such as P-PI3k, P-p7026kand P-Akt, has been proven to significantly reduce overall survival times when gliomas of all grades are considered (10). Many inhibitors of PI3K have been extensively studied, such as wortmannin and LY294002. ZSTK474 [2-(2-difluoromethylbenzimidazol-1-y1)-4,6-dimorpholino-1,3,5-triazine] is a novel PI3K inhibitor. In the present study, the synergistic anti-glioma activity of Velcade and ZSTK474 was examined using two Carmofur GBM cell lines. Treatment with both drugs inhibited proliferation and increased apoptosis of GBM cells. Detrimental proteins for therapy, such as P-Akt, P-4EBP1 and P-mTOR, were downregulated in the presence of both drugs. Taken together, treatment with the combination of Velcade and ZSTK474 was highly effective against GBM and might have a role in the future therapy for this aggressive disease. == Materials and methods == == Glioma cell lines == Human GBM cell lines U87 and U118 were maintained in Dulbeccos modified Eagles medium (Gibco, BRL) with 10% fetal calf serum (Gemini Bio-Products, Calabasas, CA, USA). Aliquots were cryopreserved in liquid nitrogen, and one aliquot of cells was kept in culture and grown to confluence. All cells were incubated at 37C in 5% CO2. == Chemicals == Proteasome inhibitor Velcade, obtained from Millennium Pharmaceuticals (Cambridge, MA, USA), was reconstituted with normal saline USP/EP at a stock concentration of 104M and stored at 20C. PI3K inhibitor ZSTK474, obtained from Selleckchem (Houston, TX, USA), was dissolved in DMSO at a stock concentration of 5103M and stored at 20C. Fresh dilutions of media were made for each experiment. == Cell growth inhibition == Cells were placed into 96-well plates at 5.0103cells/well and respectively treated with single agent alone or their combination for 72 h. Cell proliferation was measured by MTT assay. Briefly, 20l MTT solution (5 mg/ml) was added into each well for the last 4 h. Absorbance was measured at 570 nm using a spectrophotometer (Roche Molecular Biochemicals, Basel, Carmofur Switzerland). Cell growth was determined in each group and compared with that of the untreated cells. == Western blot analysis == Cells were harvested for total cell lysates with RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.5) containing a mixture of protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) as well as 1 mM NaF and 1 mM NaVO4. Carmofur Cell lysates were centrifuged at 12,000 rpm for 20 min at 4C. Supernatant was collected, and the protein concentration was measured..